Khalid Islam

- Pcovery Aps

Khalid Islam has been the Chairman and CEO of Gentium S.p.A. (a Nasdaq-listed company; 2009-2014) where he led the transition from a loss-making to a cash-flow positive and profitable company. Under his leadership the company value increased from 25m USD leading to a successful all cash 1billion USD merger with Jazz pharmaceuticals, plc.

From 1999-2008, Islam was President and CEO of Arpida AG where he transitioned the early-stage start-up to a SWX-listed company and raised 300m USD in the IPO and follow-ons. From 1987-1999, he held various positions in HMR & MMD (now Sanofi-Aventis). From 1977-1987, Islam worked in academia at Imperial College (Univ. of London) and in Milan University, where he was a contract professor. Dr. Islam is a graduate of Chelsea College and received his Ph.D. from Imperial College, University of London.

He holds several patents and has published over 85 articles in leading journals. He is an advisor to the venture group Kurma Biofund (Paris). He is a founder/Co-founder of Sirius Healthcare Partners GmbH (Zurich), Ki Consulting AG (Basel), PrevAbr LLC (D.C.), BioAim LLC (L.A.) & Life Sciences Management GmbH (Zug).

He is currently the Chairman of the Board of Directors of Pcovery Aps (Copenhagen), Adenium Aps (Copenhagen) and C10 Pharma AS (Oslo).

Related contents